Fibrinolysin consists of two polypeptide chains, one light and one heavy, linked by a disulfide bond. The light chain has a molecular weight of approximately 27,000 Da and contains the active center of Fibrinolysin; the heavy chain has a molecular weight of approximately 57,000 Da. Fibrinolysin is used as a local healing ointment when combined together with the enzyme deoxyribonuclease I (extracted from bovine pancreas). Fibrinolysin and deoxyribonuclease both act as lytic enzymes. The combination is available as ointment containing 1 BU (Biological Unit) Fibrinolysin and 666 BUs desoxyribonuclease per gram. The ointment is marketed by Pfizer under the brand name Fibrolan in a variety of countries (e.g. Switzerland). It is currently not approved in the USA.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Citalopram | The risk or severity of bleeding can be increased when Fibrinolysin is combined with Citalopram. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Fibrinolysin. |
| Levomilnacipran | The risk or severity of bleeding can be increased when Fibrinolysin is combined with Levomilnacipran. |
| Venlafaxine | The risk or severity of bleeding can be increased when Fibrinolysin is combined with Venlafaxine. |
| Oxaliplatin | The risk or severity of hemorrhage can be increased when Oxaliplatin is combined with Fibrinolysin. |
| Padeliporfin | The risk or severity of bleeding can be increased when Fibrinolysin is combined with Padeliporfin. |
| Soybean oil | The therapeutic efficacy of Fibrinolysin can be decreased when used in combination with Soybean oil. |
| Olive oil | The therapeutic efficacy of Fibrinolysin can be decreased when used in combination with Olive oil. |
| Inotersen | The risk or severity of thrombocytopenia can be increased when Inotersen is combined with Fibrinolysin. |
| Iloprost | Iloprost may increase the anticoagulant activities of Fibrinolysin. |